Over the last 7 days, the United States market has experienced a 3.0% decline, though it remains up by 4.6% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying stocks that may be undervalued involves looking for companies with strong fundamentals and growth potential that are not fully reflected in their current stock prices.
Name | Current Price | Fair Value (Est) | Discount (Est) |
NBT Bancorp (NasdaqGS:NBTB) | $39.58 | $78.07 | 49.3% |
First National (NasdaqCM:FXNC) | $18.60 | $36.87 | 49.6% |
First Bancorp (NasdaqGS:FBNC) | $36.82 | $72.67 | 49.3% |
Datadog (NasdaqGS:DDOG) | $91.88 | $178.65 | 48.6% |
DoorDash (NasdaqGS:DASH) | $179.39 | $350.88 | 48.9% |
Sotera Health (NasdaqGS:SHC) | $10.49 | $20.95 | 49.9% |
BioLife Solutions (NasdaqCM:BLFS) | $22.26 | $44.39 | 49.9% |
First Advantage (NasdaqGS:FA) | $13.79 | $27.43 | 49.7% |
MYT Netherlands Parent B.V (NYSE:MYTE) | $7.81 | $15.29 | 48.9% |
CNX Resources (NYSE:CNX) | $30.88 | $60.85 | 49.3% |
Click here to see the full list of 171 stocks from our Undervalued US Stocks Based On Cash Flows screener.
We're going to check out a few of the best picks from our screener tool.
Overview: Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems globally, with a market cap of $7.42 billion.
Operations: Repligen generates revenue from its Medical Products segment, amounting to $634.44 million.
Estimated Discount To Fair Value: 37.1%
Repligen is trading at US$132.1, significantly below its estimated fair value of US$210, making it undervalued based on cash flows. Analysts agree the stock price could rise by 43%. Despite a low future Return on Equity forecast of 6.1%, Repligen's revenue is expected to grow faster than the market at 13.6% annually. However, recent challenges include delayed SEC filings and a net loss in Q4 2024, impacting investor confidence.
Overview: Coeur Mining, Inc. is a gold and silver producer operating in the United States, Canada, and Mexico with a market cap of $3.90 billion.
Operations: The company's revenue segments include Wharf at $234.01 million, Palmarejo at $379.06 million, Rochester at $215.81 million, and Kensington at $225.13 million.
Estimated Discount To Fair Value: 34.1%
Coeur Mining, with a trading price of US$6.27, is undervalued based on cash flows, as it sits below the estimated fair value of US$9.52. Recent profitability and a forecasted 40% annual earnings growth highlight its potential despite past shareholder dilution. Revenue growth is expected to outpace the broader U.S. market at 14.4% annually. The company reported significant improvements in net income for 2024 and increased mineral reserves, enhancing its operational outlook.
Overview: CareTrust REIT, Inc. primarily focuses on acquiring, financing, developing, and owning real estate properties leased to third-party tenants in the healthcare sector, with a market cap of approximately $5.33 billion.
Operations: Revenue is primarily generated from investments in healthcare-related real estate assets, totaling $296.29 million.
Estimated Discount To Fair Value: 47.4%
CareTrust REIT, priced at US$28.62, is significantly undervalued based on cash flows with a fair value estimate of US$54.39. Despite recent shareholder dilution and a dividend not fully covered by earnings, its earnings grew 133.7% last year and are forecasted to grow 32.54% annually, outpacing the U.S. market's growth rate of 13.5%. Recent acquisitions totaling US$55 million funded by cash on hand underscore strategic expansion efforts enhancing future revenue streams.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:RGEN NYSE:CDE and NYSE:CTRE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。